These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 25567227)

  • 1. Antimicrobial heteroresistance: an emerging field in need of clarity.
    El-Halfawy OM; Valvano MA
    Clin Microbiol Rev; 2015 Jan; 28(1):191-207. PubMed ID: 25567227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heteroresistance: a concern of increasing clinical significance?
    Falagas ME; Makris GC; Dimopoulos G; Matthaiou DK
    Clin Microbiol Infect; 2008 Feb; 14(2):101-4. PubMed ID: 18093235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms and clinical relevance of bacterial heteroresistance.
    Andersson DI; Nicoloff H; Hjort K
    Nat Rev Microbiol; 2019 Aug; 17(8):479-496. PubMed ID: 31235888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What's new on the antimicrobial horizon?
    Song JH
    Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S207-13. PubMed ID: 19134521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why is antibiotic resistance a deadly emerging disease?
    Courvalin P
    Clin Microbiol Infect; 2016 May; 22(5):405-7. PubMed ID: 26806259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotic resistance.
    Frieri M; Kumar K; Boutin A
    J Infect Public Health; 2017; 10(4):369-378. PubMed ID: 27616769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The high prevalence of antibiotic heteroresistance in pathogenic bacteria is mainly caused by gene amplification.
    Nicoloff H; Hjort K; Levin BR; Andersson DI
    Nat Microbiol; 2019 Mar; 4(3):504-514. PubMed ID: 30742072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Glycopeptide heteroresistance and tolerance in hospital grampositive isolates: "invisible" phenomena to the clinician with clinical implications?].
    Aguilar L; Giménez MJ; Barberán J
    Rev Esp Quimioter; 2009 Dec; 22(4):173-9. PubMed ID: 20082037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel antibiotics: are we still in the pre-post-antibiotic era?
    Draenert R; Seybold U; Grützner E; Bogner JR
    Infection; 2015 Apr; 43(2):145-51. PubMed ID: 25701222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative evaluation of the VITEK 2, disk diffusion, etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains.
    Lo-Ten-Foe JR; de Smet AM; Diederen BM; Kluytmans JA; van Keulen PH
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3726-30. PubMed ID: 17646414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic heteroresistance in ESKAPE pathogens, from bench to bedside.
    Roch M; Sierra R; Andrey DO
    Clin Microbiol Infect; 2023 Mar; 29(3):320-325. PubMed ID: 36270588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to fight antimicrobial resistance.
    Foucault C; Brouqui P
    FEMS Immunol Med Microbiol; 2007 Mar; 49(2):173-83. PubMed ID: 17181560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discerning the role of polymicrobial biofilms in the ascent, prevalence, and extent of heteroresistance in clinical practice.
    Lopes SP; Jorge P; Sousa AM; Pereira MO
    Crit Rev Microbiol; 2021 Mar; 47(2):162-191. PubMed ID: 33527850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacterial Heterogeneity and Antibiotic Survival: Understanding and Combatting Persistence and Heteroresistance.
    Dewachter L; Fauvart M; Michiels J
    Mol Cell; 2019 Oct; 76(2):255-267. PubMed ID: 31626749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance.
    Lee SY; Kuti JL; Nicolau DP
    Surg Infect (Larchmt); 2005; 6(3):283-95. PubMed ID: 16201938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Calculated antibiotic therapy in gastroenterologic infections].
    Braun RW
    Praxis (Bern 1994); 2003 Aug; 92(33):1343-9. PubMed ID: 14502790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial resistance determinants and future control.
    Harbarth S; Samore MH
    Emerg Infect Dis; 2005 Jun; 11(6):794-801. PubMed ID: 15963271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The challenge of antibiotic resistant bacterial pathogens: the medical need, the market and prospects for new antimicrobial agents.
    Payne D; Tomasz A
    Curr Opin Microbiol; 2004 Oct; 7(5):435-8. PubMed ID: 15451496
    [No Abstract]   [Full Text] [Related]  

  • 19. Persisters and beyond: mechanisms of phenotypic drug resistance and drug tolerance in bacteria.
    Kester JC; Fortune SM
    Crit Rev Biochem Mol Biol; 2014; 49(2):91-101. PubMed ID: 24328927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bacteria fight back.
    Taubes G
    Science; 2008 Jul; 321(5887):356-61. PubMed ID: 18635788
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 30.